RESUMO
BACKGROUND: Psittacosis, which is also known as parrot fever, is Chlamydia psittaci (C. psittaci) caused infectious disease. The clinical manifestations vary from asymptomatic infection to severe atypical pneumonia or even fatal meningitis. Early recognition of psittacosis is difficult because of its nonspecific clinical manifestations. Culture and gene probe techniques for C. psittaci are not available for routine clinical use, which makes the diagnosis difficult too. Although psittacosis has increasingly been recognized and reported in recent years, cure of severe pneumonia complicated with meningitis, with etiologic diagnosis aided by the use of metagenomic next-generation sequencing (mNGS), is still uncommon. So, it is necessary to report and review such potentially fatal case. CASE PRESENTATION: This report describes a 54-year-old woman with C. psittaci caused severe atypical pneumonia and meningitis. She presented with symptoms of fever, dry cough and dyspnea, accompanied by prominent headache. Her condition deteriorated rapidly to respiratory failure and lethargy under the treatment of empirical antibacterial agents, and was treated with invasive mechanical ventilation soon. She denied contact with birds, poultry or horses, but unbiased mNGS of both the bronchoalveolar lavage fluid (BALF) and the cerebrospinal fluid (CSF) identified sequence reads corresponding to C. psittaci infection, and there was no sequence read corresponding to other probable pathogens. Combined use of targeted antimicrobial agents of tetracyclines, macrolides and fluoroquinolones was carried out, and the patient's condition improved and she was discharged home 28 days later. Her status returned close to premorbid condition on day 60 of follow-up. CONCLUSIONS: When clinicians come across a patient with atypical pneumonia accompanied by symptoms of meningitis, psittacosis should be taken into consideration. mNGS is a promising detection method in such condition and is recommended.
Assuntos
Pneumonia por Clamídia/diagnóstico , Chlamydophila psittaci/isolamento & purificação , Sequenciamento de Nucleotídeos em Larga Escala , Meningite/diagnóstico , Metagenoma , Psitacose/diagnóstico , Animais , Anti-Infecciosos/uso terapêutico , Pneumonia por Clamídia/tratamento farmacológico , Feminino , Fluoroquinolonas/uso terapêutico , Humanos , Macrolídeos/uso terapêutico , Meningite/tratamento farmacológico , Pessoa de Meia-Idade , Psitacose/tratamento farmacológico , Tetraciclinas/uso terapêutico , Resultado do TratamentoRESUMO
The in vitro activities of omadacycline, azithromycin, doxycycline, moxifloxacin, and levofloxacin were tested against 15 isolates of Chlamydia pneumoniae The minimum inhibitory concentration at which 90% of the isolates of C. pneumoniae were inhibited by omadacycline was 0.25 µg/ml (range, 0.03 to 0.5 µg/ml).
Assuntos
Antibacterianos/farmacologia , Chlamydophila pneumoniae/efeitos dos fármacos , Tetraciclinas/farmacologia , Azitromicina/farmacologia , Linhagem Celular , Pneumonia por Clamídia/tratamento farmacológico , Pneumonia por Clamídia/microbiologia , Chlamydophila pneumoniae/isolamento & purificação , Doxiciclina/farmacologia , Humanos , Levofloxacino/farmacologia , Testes de Sensibilidade Microbiana , Moxifloxacina/farmacologiaRESUMO
Chlamydia trachomatis is a gram-negative bacterium that infects the columnar epithelium of the cervix, urethra, and rectum, as well as nongenital sites such as the lungs and eyes. The bacterium is the cause of the most frequently reported sexually transmitted disease in the United States, which is responsible for more than 1 million infections annually. Most persons with this infection are asymptomatic. Untreated infection can result in serious complications such as pelvic inflammatory disease, infertility, and ectopic pregnancy in women, and epididymitis and orchitis in men. Men and women can experience chlamydia-induced reactive arthritis. Treatment of uncomplicated cases should include azithromycin or doxycycline. Screening is recommended in all women younger than 25 years, in all pregnant women, and in women who are at increased risk of infection. Screening is not currently recommended in men. In neonates and infants, the bacterium can cause conjunctivitis and pneumonia. Adults may also experience conjunctivitis caused by chlamydia. Trachoma is a recurrent ocular infection caused by chlamydia and is endemic in the developing world.
Assuntos
Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Infecções por Chlamydia/diagnóstico , Infecções por Chlamydia/tratamento farmacológico , Chlamydia trachomatis , Doxiciclina/uso terapêutico , Programas de Rastreamento , Adolescente , Adulto , Infecções por Chlamydia/complicações , Infecções por Chlamydia/epidemiologia , Infecções por Chlamydia/microbiologia , Infecções por Chlamydia/prevenção & controle , Chlamydia trachomatis/isolamento & purificação , Pneumonia por Clamídia/diagnóstico , Pneumonia por Clamídia/tratamento farmacológico , Epididimite/microbiologia , Feminino , Humanos , Incidência , Infertilidade Feminina/microbiologia , Linfogranuloma Venéreo/diagnóstico , Linfogranuloma Venéreo/tratamento farmacológico , Masculino , Orquite/microbiologia , Doença Inflamatória Pélvica/microbiologia , Guias de Prática Clínica como Assunto , Gravidez , Gravidez Ectópica/microbiologia , Prevalência , Fatores de Risco , Infecções Sexualmente Transmissíveis/diagnóstico , Infecções Sexualmente Transmissíveis/tratamento farmacológico , Tracoma/diagnóstico , Tracoma/tratamento farmacológico , Resultado do Tratamento , Estados Unidos/epidemiologiaRESUMO
Psittacosis is a rare disease caused by Chlamydophila psittaci, an intracellular bacteria transmitted by contaminated birds. The clinical and radiological presentations are nonspecific. We describe a case of a 42-year-old woman, with known exposure to birds, who presented to the emergency department with one-week evolution of myalgia, polyarthritis, and respiratory symptoms. At admission, she had fever, respiratory failure, raised inflammatory markers and bilateral interstitial infiltrates at chest radiography. Considering the clinical findings and epidemiological background, we raised the hypothesis of a Chlamydophila psittaci atypical pneumonia that was serologically confirmed. Tetracyclines are the mainstay of treatment and the macrolides are an effective alternative. We highlight the importance of the epidemiological context in the early diagnosis and treatment of this infection.
A psitacose é uma entidade rara provocada pela Chlamydophila psittaci, uma bactéria intracelular obrigatória que se transmite através do contacto com aves contaminadas. A apresentação clínica e imagiológica é inespecífica. Reporta-se o caso clínico de uma mulher de 42 anos, com história de exposição a pássaros, que se apresenta no Serviço de Urgência com um quadro de mialgias, poliartralgias e clínica de infeção respiratória, com uma semana de evolução. À admissão, encontrava-se febril, com insuficiência respiratória do tipo 1, elevação dos parâmetros inflamatórios e infiltrados intersticiais difusos bilaterais na radiografia de tórax. Considerando o quadro clínico e o contexto epidemiológico de risco, colocou-se a hipótese de pneumonia atípica por Chlamydophila psittaci, confirmada serologicamente. As tetraciclinas são o esteio do tratamento, sendo os macrólidos uma alternativa eficaz. Realça-se a importância do contexto epidemiológico, para uma abordagem diagnóstica e terapêutica apropriadas.
Assuntos
Pneumonia por Clamídia/diagnóstico , Psitacose/diagnóstico , Adulto , Agapornis/microbiologia , Animais , Antibacterianos/uso terapêutico , Pneumonia por Clamídia/tratamento farmacológico , Pneumonia por Clamídia/microbiologia , Chlamydophila psittaci , Diagnóstico Precoce , Feminino , Humanos , Macrolídeos/uso terapêutico , Psitacose/tratamento farmacológico , Tetraciclina/uso terapêuticoAssuntos
Pneumonia por Clamídia/diagnóstico , Chlamydophila pneumoniae/isolamento & purificação , Meios de Comunicação de Massa , Infecções Respiratórias/microbiologia , Antibacterianos/economia , Antibacterianos/uso terapêutico , Azitromicina/economia , Azitromicina/uso terapêutico , Pneumonia por Clamídia/tratamento farmacológico , Pneumonia por Clamídia/epidemiologia , Uso de Medicamentos , História do Século XXI , Humanos , Infecções Respiratórias/tratamento farmacológico , Esqui , Suécia/epidemiologiaAssuntos
Pneumonia por Clamídia/diagnóstico , Chlamydophila pneumoniae , Infecções Respiratórias/microbiologia , Antibacterianos/uso terapêutico , Pneumonia por Clamídia/complicações , Pneumonia por Clamídia/tratamento farmacológico , Síndrome de Fadiga Crônica/diagnóstico , Síndrome de Fadiga Crônica/tratamento farmacológico , Síndrome de Fadiga Crônica/microbiologia , Humanos , Meios de Comunicação de Massa , Jornais como Assunto , Infecções Respiratórias/diagnóstico , Infecções Respiratórias/tratamento farmacológico , Esqui , SuéciaRESUMO
BACKGROUND: Chlamydia pneumonia is reported to account for a relatively large number of cases of CAP. In elderly patients in particular, the clinical presentation can be a severe form of diffuse interstitial pneumonia. The chest X-ray presentation is aspecific. Lung US can show a typical pattern of diffuse interstitial lung syndrome; in some cases, like the present one, the association of multiple B lines with a coarse and thickened pleural line points to a more likely diagnosis of interstitial pneumonia. CASE REPORT: We present the case of an 87-year-old woman with severe interstitial chlamydial pneumonia, for whom lung US was very useful for directing diagnosis and for follow-up during therapy. CONCLUSIONS: The use of lung US in the diagnosis of interstitial syndrome is likely to improve the care of patients in whom the diagnosis is a consideration; it offers better characterization than a chest X-ray and is free from CT radiation. Furthermore, the concept of using lung US for monitoring a patient is one of the major innovations that has emerged from recent studies.
Assuntos
Doenças Pulmonares Intersticiais/diagnóstico por imagem , Pulmão/diagnóstico por imagem , Ultrassonografia , Idoso de 80 Anos ou mais , Pneumonia por Clamídia/diagnóstico por imagem , Pneumonia por Clamídia/tratamento farmacológico , Chlamydophila pneumoniae , Diagnóstico Diferencial , Feminino , Humanos , Pulmão/efeitos dos fármacos , Doenças Pulmonares Intersticiais/tratamento farmacológicoRESUMO
Chronic bacterial infection is implicated in both the development and severity of asthma. The atypical bacteria Mycoplasma pneumoniae and Chlamydophila pneumoniae have been identified in the airways of asthmatics and correlated with clinical features such as adult onset, exacerbation risks, steroid sensitivity, and symptom control. Asthmatic patients with evidence of bacterial infection may benefit from antibiotic treatment directed towards these atypical organisms. Examination of the airway microbiome may identify microbial communities that confer risk for or protection from severe asthma.
Assuntos
Asma/etiologia , Asma/fisiopatologia , Infecções/complicações , Infecções/microbiologia , Animais , Antibacterianos/uso terapêutico , Asma/diagnóstico , Asma/tratamento farmacológico , Pneumonia por Clamídia/complicações , Pneumonia por Clamídia/diagnóstico , Pneumonia por Clamídia/tratamento farmacológico , Pneumonia por Clamídia/microbiologia , Doença Crônica , Progressão da Doença , Humanos , Infecções/diagnóstico , Infecções/tratamento farmacológico , Macrolídeos/uso terapêutico , Pneumonia por Mycoplasma/complicações , Pneumonia por Mycoplasma/diagnóstico , Pneumonia por Mycoplasma/tratamento farmacológico , Pneumonia por Mycoplasma/microbiologia , Índice de Gravidade de DoençaRESUMO
Chlamydia trachomatis causes sexually transmitted diseases with infertility, pelvic inflammatory disease and neonatal pneumonia as complications. The duration of urogenital mouse models with the strict mouse pathogen C. muridarum addressing vaginal shedding, pathological changes of the upper genital tract or infertility is rather long. Moreover, vaginal C. trachomatis application usually does not lead to the complications feared in women. A fast-to-perform mouse model is urgently needed to analyze new antibiotics, vaccine candidates, immune responses (in gene knockout animals) or mutants of C. trachomatis. To complement the valuable urogenital model with a much faster and quantifiable screening method, we established an optimized lung infection model for the human intracellular bacterium C. trachomatis serovar D (and L2) in immunocompetent C57BL/6J mice. We demonstrated its usefulness by sensitive determination of antibiotic effects characterizing advantages and limitations achievable by early or delayed short tetracycline treatment and single-dose azithromycin application. Moreover, we achieved partial acquired protection in reinfection with serovar D indicating usability for vaccine studies, and showed a different course of disease in absence of complement factor C3. Sensitive monitoring parameters were survival rate, body weight, clinical score, bacterial load, histological score, the granulocyte marker myeloperoxidase, IFN-γ, TNF-α, MCP-1 and IL-6.
Assuntos
Antibacterianos/uso terapêutico , Vacinas Bacterianas/imunologia , Chlamydia trachomatis/efeitos dos fármacos , Chlamydia trachomatis/fisiologia , Pneumonia por Clamídia/tratamento farmacológico , Pneumonia por Clamídia/prevenção & controle , Interações Hospedeiro-Patógeno , Animais , Antibacterianos/farmacologia , Carga Bacteriana , Biópsia , Linhagem Celular , Pneumonia por Clamídia/microbiologia , Pneumonia por Clamídia/mortalidade , Complemento C3/genética , Complemento C3/imunologia , Citocinas/biossíntese , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Interações Hospedeiro-Patógeno/efeitos dos fármacos , Interações Hospedeiro-Patógeno/imunologia , Humanos , Imunoglobulina G/imunologia , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Pulmão/microbiologia , Pulmão/patologia , Camundongos , Camundongos Knockout , Peroxidase/metabolismoRESUMO
OBJECTIVE: Chlamydophila pneumoniae is a common agent of respiratory infections. Severe acute neurological infections are very infrequently linked to this bacterium. We report such a case and give a rapid overview of published cases of acute encephalitis occurring after a respiratory infection due to C. pneumoniae. PATIENT AND METHODS: A 12-year-old child without any prior medical history was hospitalized for encephalitis associated to respiratory symptoms. RESULTS: C. pneumoniae DNA was identified by multiplex PCR assay in respiratory secretions and C. pneumoniae IgM and IgG antibodies were assessed in the serum. This bacterium was not detected in CSF, nor was any other pathogen. A macrolide treatment was prescribed for two weeks. The outcome was good without any sequels. CONCLUSIONS: This observation correlates to the few similar cases reported in the medical literature. C. pneumoniae must be suggested in the etiological diagnosis of acute encephalitis, notably in a context of respiratory infection, when no more common cause can be identified.
Assuntos
Pneumonia por Clamídia/complicações , Chlamydophila pneumoniae/isolamento & purificação , Encefalite/etiologia , Doença Aguda , Antibacterianos/uso terapêutico , Anticorpos Antibacterianos/sangue , Criança , Pneumonia por Clamídia/tratamento farmacológico , Pneumonia por Clamídia/microbiologia , Chlamydophila pneumoniae/imunologia , DNA Bacteriano/análise , Dor de Orelha/etiologia , Encefalite/líquido cefalorraquidiano , Encefalite/tratamento farmacológico , Hematúria/etiologia , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Imunoglobulina M/sangue , Imunoglobulina M/imunologia , Josamicina/uso terapêutico , Masculino , Sinusite/etiologia , Vômito/etiologiaRESUMO
A newborn colonized with Chlamydia trachomatis will often show symptoms of conjunctivitis and/or pneumonia. We report a case of interstitial pneumonia caused by C. trachomatis in a 2-month-old boy admitted with RSV. We point to the importance of C. trachomatis in the differential diagnostics of an infant with respiratory symptoms even in the presence of additional infectious agents.
Assuntos
Chlamydia trachomatis/isolamento & purificação , Pneumonia por Clamídia/diagnóstico , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Pneumonia por Clamídia/diagnóstico por imagem , Pneumonia por Clamídia/tratamento farmacológico , Claritromicina/administração & dosagem , Claritromicina/uso terapêutico , Humanos , Lactente , Doenças Pulmonares Intersticiais/diagnóstico por imagem , Doenças Pulmonares Intersticiais/tratamento farmacológico , Doenças Pulmonares Intersticiais/microbiologia , Masculino , Radiografia , Vírus Sincicial Respiratório Humano/isolamento & purificação , Fatores de TempoRESUMO
BACKGROUND: Although most experts recommend empirical antibiotic treatment, covering also atypical bacteria, for patients admitted to an intensive care unit (ICU), the data are not clear for patients admitted to a general ward. European guidelines recommend starting empirical treatment with a beta-lactam antibiotic with or without a macrolide, but the with/without is not clarified. We investigated whether the use of antibiotic coverage for atypical pathogens was guided by clinical parameters. METHODS: We retrospectively analysed 300 patients hospitalised with community-acquired pneumonia. Four parameters for possible atypical pneumonia (age <55 years, abdominal symptoms, sodium <130 mmol/l, immunosuppression) and three for pneumonia severity (pneumonia severity index [PSI], ICU admission, pO2 <8 kPa (60 mm Hg) or O2 saturation <90%) were defined and correlated with the probability of coverage for atypical pathogens. Correlations were calculated using the chi-square test for 2 x 2 tables. RESULTS: Patients younger than 55 years significantly more likely to receive coverage for atypical pathogens than older patients (odds ratio [OR] 2.68; 95% confidence interval [CI] 1.3-5.5, p = 0.009). In patients with a PSI >III the proportion receiving coverage for atypical bacteria was even smaller than in patients with less severe pneumonia (OR 0.77; 95% CI 0.60-0.99, p = 0.03), but no difference was found for PSI >IV compared with PSI ≤IV (OR = 1.03; 95% CI 0.61-1.74, p = 0.9). The other clinical parameters had no effect on antibiotic coverage: ICU admission (OR =1.39; 95% CI 0.87-2.4, p = 0.15); pO2 >8 kPa or O2-Saturation >90% (OR 1.36; 95% CI 0.85-2.17, p = 0.19); abdominal symptoms (OR 1.06; 95% CI 0.51-2.25, p = 0.88); sodium <130 mmol/l (OR 0.63; 95% CI 0.29-1.36, p = 0.2) or immunosuppression (OR 1.007; 95% CI 0.462-44, p = 1). There was also no correlation between the number of clinical parameters present and the coverage of atypical pathogens (r = 0.48). Mortality was no different between patients in whom atypical pathogens were covered compared with those with beta-lactam therapy alone (OR 1.2; 95% CI 0.66-2.25, p = 0.43). CONCLUSION: Physicians have difficulties deciding when to cover atypical pathogens in hospitalised patients with community-acquired pneumonia. Guidelines should clarify under what circumstances combination therapy is warranted.
Assuntos
Antibacterianos/uso terapêutico , Infecções Comunitárias Adquiridas/tratamento farmacológico , Fidelidade a Diretrizes/estatística & dados numéricos , Macrolídeos/uso terapêutico , Pneumonia Bacteriana/tratamento farmacológico , Guias de Prática Clínica como Assunto , beta-Lactamas/uso terapêutico , Adulto , Fatores Etários , Idoso , Pneumonia por Clamídia/tratamento farmacológico , Claritromicina/uso terapêutico , Infecções Comunitárias Adquiridas/imunologia , Quimioterapia Combinada/estatística & dados numéricos , Hospitalização , Humanos , Hospedeiro Imunocomprometido , Doença dos Legionários/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Razão de Chances , Pneumonia Bacteriana/imunologia , Pneumonia por Mycoplasma/tratamento farmacológico , Pneumonia Pneumocócica/tratamento farmacológico , Padrões de Prática Médica/estatística & dados numéricos , Estudos Retrospectivos , Índice de Gravidade de DoençaRESUMO
INTRODUCTION: Chlamydiae are obligate intracellular bacterial pathogens whose entry into mucosal epithelial cells is required for intracellular survival and subsequent growth. The life cycle of Chlamydia spp. and the ability to cause persistent, often subclinical infection, has major ramifications for diagnosis and treatment of C. trachomatis and C. pneumoniae infections in humans. AREAS COVERED: This up-to-date review describes the current state of knowledge of antimicrobial susceptibilities and treatment of genital infections due to C. trachomatis and respiratory infections due to C. pneumoniae. EXPERT OPINION: Chlamydiae are susceptible to antibiotics that interfere with DNA and protein synthesis, including tetracyclines, macrolides and quinolones, which are the compounds that have been most extensively studied and used for treatment of human infection. Treatment of individuals with C. trachomatis genital infection prevents sexual transmission and complications, including pelvic inflammatory disease. Treatment of pregnant women will prevent the transmission of infection to infants during delivery. The benefits of treatment of respiratory infections due to C. pneumoniae are more difficult to assess, primarily because of the lack of FDA-approved, specific diagnostic tests for detection of the organism in clinical samples. The majority of published studies have relied on serology for diagnosis, making it difficult to assess microbiologic efficacy.
Assuntos
Anti-Infecciosos/farmacologia , Anti-Infecciosos/uso terapêutico , Infecções por Chlamydia/tratamento farmacológico , Chlamydia trachomatis/efeitos dos fármacos , Pneumonia por Clamídia/tratamento farmacológico , Animais , Humanos , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
No disponible